SG11201808848SA - Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid - Google Patents
Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaidInfo
- Publication number
- SG11201808848SA SG11201808848SA SG11201808848SA SG11201808848SA SG11201808848SA SG 11201808848S A SG11201808848S A SG 11201808848SA SG 11201808848S A SG11201808848S A SG 11201808848SA SG 11201808848S A SG11201808848S A SG 11201808848SA SG 11201808848S A SG11201808848S A SG 11201808848SA
- Authority
- SG
- Singapore
- Prior art keywords
- nsaid
- antihypertensive
- pharmaceutical composition
- converting enzyme
- enzyme inhibitor
- Prior art date
Links
- 239000005541 ACE inhibitor Substances 0.000 title 1
- 230000003276 anti-hypertensive effect Effects 0.000 title 1
- 239000002876 beta blocker Substances 0.000 title 1
- 229940097320 beta blocking agent Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1653502A FR3050380B1 (fr) | 2016-04-20 | 2016-04-20 | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
| PCT/FR2017/050929 WO2017182754A1 (fr) | 2016-04-20 | 2017-04-19 | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808848SA true SG11201808848SA (en) | 2018-11-29 |
Family
ID=56943614
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808848SA SG11201808848SA (en) | 2016-04-20 | 2017-04-19 | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid |
| SG10202009894PA SG10202009894PA (en) | 2016-04-20 | 2017-04-19 | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009894PA SG10202009894PA (en) | 2016-04-20 | 2017-04-19 | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3445342A1 (fr) |
| KR (1) | KR102267965B1 (fr) |
| CN (1) | CN109069438A (fr) |
| BR (1) | BR112018070968A2 (fr) |
| EA (1) | EA201892354A1 (fr) |
| FR (1) | FR3050380B1 (fr) |
| GE (2) | GEP20217310B (fr) |
| MA (1) | MA44728A (fr) |
| MX (1) | MX389586B (fr) |
| PH (1) | PH12018502155B1 (fr) |
| RU (1) | RU2756320C2 (fr) |
| SG (2) | SG11201808848SA (fr) |
| TN (1) | TN2018000344A1 (fr) |
| UA (1) | UA125511C2 (fr) |
| WO (1) | WO2017182754A1 (fr) |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2645710C2 (de) | 1976-10-09 | 1985-06-27 | Merck Patent Gmbh, 6100 Darmstadt | Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung |
| FR2503155A2 (fr) | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2620709B1 (fr) | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
| FR2807431B1 (fr) | 2000-04-06 | 2002-07-19 | Adir | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables |
| GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| AR036187A1 (es) | 2001-07-24 | 2004-08-18 | Adir | Un proceso para la preparacion de perindopril, compuestos analogos y sus sales, compuesto intermediario 2,5-dioxo-oxazolidina y proceso para preparar un intermediario |
| FR2827860B1 (fr) | 2001-07-24 | 2004-12-10 | Servier Lab | Nouveau procede de synthese de derives de l'acide (2s, 3as, 7as)-1-[(s)-alanyl]-octahydro-1h-indole-2-carboxyline et application a la synthese du perindopril |
| ATE365714T1 (de) | 2002-01-30 | 2007-07-15 | Servier Lab | Verfahren zur herstellung von hochreinem perindopril und zwischenverbindungen nützlich in der synthese |
| FR2838648B1 (fr) | 2002-04-18 | 2004-05-21 | Servier Lab | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
| ATE395913T1 (de) | 2003-02-28 | 2008-06-15 | Servier S A Lab | Verfahren zur herstellung von perindopril |
| DE60301930T2 (de) | 2003-02-28 | 2006-07-27 | Les Laboratoires Servier | Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salze |
| PT1321471E (pt) | 2003-03-12 | 2005-07-29 | Servier Lab | Novo processo de sintese do perindopril e dos seus sais aceitaveis sob o ponto de vista farmaceutico |
| SI1367061T1 (sl) | 2003-06-30 | 2006-04-30 | Servier Lab | Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli |
| SI1362864T1 (sl) | 2003-06-30 | 2007-08-31 | Servier Lab | Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli |
| EP1648422A4 (fr) * | 2003-07-28 | 2007-09-19 | Reddys Lab Inc Dr | Traitement et prevention d'accidents cardiovasculaires |
| DK1367062T3 (da) | 2003-07-31 | 2007-01-02 | Servier Lab | Ny fremgangsmåde til syntese af perindopril og farmaceutisk acceptable salte heraf |
| ES2271498T3 (es) | 2003-07-31 | 2007-04-16 | Les Laboratoires Servier | Nuevo procedimiento de sintesis de perindopril y de sus sales farmaceuticamente aceptables. |
| EP1380591B1 (fr) | 2003-08-29 | 2005-11-16 | Les Laboratoires Servier | Nouveau procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
| ES2250853T3 (es) | 2003-08-29 | 2006-04-16 | Les Laboratoires Servier | Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables. |
| DE60308102T2 (de) | 2003-08-29 | 2007-06-21 | Les Laboratoires Servier | Verfahren für die Synthese von Perindopril und seiner pharmazeutisch annehmbaren Salzen |
| DE60311942T2 (de) | 2003-11-19 | 2007-12-06 | Les Laboratoires Servier | Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen |
| EP1422236B1 (fr) | 2003-11-19 | 2007-02-14 | Les Laboratoires Servier | Procédé de synthèse du perindopril et de ses sels pharmaceutiquement acceptables |
| SI1420029T1 (sl) | 2003-12-10 | 2008-08-31 | Servier Lab | Postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli |
| SI21800A (sl) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| FR2894825B1 (fr) | 2005-12-21 | 2010-12-03 | Servier Lab | Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent |
| FR2897866B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2897865B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| CN101024082A (zh) * | 2007-04-06 | 2007-08-29 | 张士东 | 一种全面预防和治疗心脑血管疾病复方药及其应用 |
| AU2009263737B2 (en) | 2008-06-24 | 2013-10-24 | Tianish Laboratories Private Limited | Novel polymorphic forms of Perindopril (L)-Arginine and process for the preparation thereof |
| HU230877B1 (hu) | 2008-09-30 | 2018-11-29 | EGIS Gyógyszergyár NyR | Stabil kombinációs gyógyszerkészítmény |
| US9789187B2 (en) * | 2009-02-11 | 2017-10-17 | Cadila Pharmaceuticals Limited | Stable pharmaceutical composition for atherosclerosis |
| EP2424509A4 (fr) * | 2009-04-30 | 2012-11-07 | Reddys Lab Ltd Dr | Formulations de combinaison de médicament à dose fixe |
| FR2961105B1 (fr) | 2010-06-15 | 2013-02-08 | Servier Lab | Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque |
| FR2985511B1 (fr) | 2012-01-05 | 2014-01-03 | Servier Lab | Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
-
2016
- 2016-04-19 PH PH1/2018/502155A patent/PH12018502155B1/en unknown
- 2016-04-20 FR FR1653502A patent/FR3050380B1/fr not_active Expired - Fee Related
-
2017
- 2017-04-19 GE GEAP201714923A patent/GEP20217310B/en unknown
- 2017-04-19 CN CN201780023915.6A patent/CN109069438A/zh active Pending
- 2017-04-19 EA EA201892354A patent/EA201892354A1/ru unknown
- 2017-04-19 MX MX2018012790A patent/MX389586B/es unknown
- 2017-04-19 TN TNP/2018/000344A patent/TN2018000344A1/en unknown
- 2017-04-19 KR KR1020187033434A patent/KR102267965B1/ko not_active Expired - Fee Related
- 2017-04-19 BR BR112018070968A patent/BR112018070968A2/pt not_active Application Discontinuation
- 2017-04-19 GE GEAP202114923A patent/GEAP202114923A/en unknown
- 2017-04-19 RU RU2018140193A patent/RU2756320C2/ru active
- 2017-04-19 MA MA044728A patent/MA44728A/fr unknown
- 2017-04-19 SG SG11201808848SA patent/SG11201808848SA/en unknown
- 2017-04-19 UA UAA201811111A patent/UA125511C2/uk unknown
- 2017-04-19 WO PCT/FR2017/050929 patent/WO2017182754A1/fr not_active Ceased
- 2017-04-19 EP EP17722115.7A patent/EP3445342A1/fr not_active Withdrawn
- 2017-04-19 SG SG10202009894PA patent/SG10202009894PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018140193A3 (fr) | 2020-06-03 |
| PH12018502155B1 (en) | 2024-03-27 |
| PH12018502155A1 (en) | 2019-07-15 |
| FR3050380B1 (fr) | 2020-07-10 |
| FR3050380A1 (fr) | 2017-10-27 |
| MA44728A (fr) | 2019-02-27 |
| KR102267965B1 (ko) | 2021-06-21 |
| MX389586B (es) | 2025-03-20 |
| WO2017182754A1 (fr) | 2017-10-26 |
| GEAP202114923A (en) | 2021-07-12 |
| RU2018140193A (ru) | 2020-05-20 |
| KR20180132911A (ko) | 2018-12-12 |
| UA125511C2 (uk) | 2022-04-13 |
| TN2018000344A1 (en) | 2020-06-15 |
| EA201892354A1 (ru) | 2019-04-30 |
| BR112018070968A2 (pt) | 2019-01-29 |
| RU2756320C2 (ru) | 2021-09-29 |
| CN109069438A (zh) | 2018-12-21 |
| EP3445342A1 (fr) | 2019-02-27 |
| SG10202009894PA (en) | 2020-11-27 |
| GEP20217310B (en) | 2021-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3774750A4 (fr) | Immunomodulateurs, compositions et procédés associés | |
| EP3283435A4 (fr) | Composition, matériaux sous forme de particules et procédés de fabrication de matériaux sous forme de particules | |
| EP3268045A4 (fr) | Formulations d'épinéphrine | |
| EP3357513A4 (fr) | Composition pharmaceutique et application de cette dernière | |
| CA3273336A1 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
| EP3331530A4 (fr) | Inhibiteurs de mthfd2 et utilisation desdits inhibiteurs | |
| GB201917300D0 (en) | Post-quantum secure messaging | |
| EP3254667A4 (fr) | Composition photodurcissable, prothèse dentaire et dentier | |
| EP3263122A4 (fr) | Peptide pour prévenir la perte de l'audition et composition le comprenant | |
| EP3208326A4 (fr) | Composition de matériau de friction, matériau de friction, et élément de friction | |
| EP3225674A4 (fr) | Composition pour matériau de frottement, et matériau de frottement et élément de frottement utilisant ladite composition pour matériau de frottement | |
| EP3676247B8 (fr) | Dérivés d'aztréonam et utilisations associées | |
| CA3255361A1 (en) | Compositions comprising .alpha.-ketoglutarate for extending lifespan and healthspan | |
| EP3594309A4 (fr) | Composition de matériau à friction, matériau à friction et élément à friction | |
| EP3235891A4 (fr) | Composition et élément électroluminescent mettant en uvre cette composition | |
| EP3705127A4 (fr) | Composition contenant un extrait desalvia miltiorrhiza | |
| EP3275454A4 (fr) | Composition pharmaceutique contenant de la silybine, ve et l-carnitine | |
| EP3712143A4 (fr) | Composé de quinazolinone et son application | |
| EP3731840A4 (fr) | Inhibiteurs de la nadph oxydase et leur utilisation | |
| EP3701930A4 (fr) | Composition dentaire | |
| ZA202104192B (en) | Mmpl3 inhibitors, compositions and uses thereof | |
| EP3596082A4 (fr) | Inhibiteurs de cdpk1, compositions et procédés associés | |
| EP3664604A4 (fr) | Composition herbicide et procédé | |
| IL280078A (en) | Thrombin inhibitors, preparations and their uses | |
| EP3612230A4 (fr) | Compositions de palbociclib et méthodes associées |